Hidradenitis Suppurativa Treatment Market Share & Trends [2033]

Hidradenitis Suppurativa Treatment Market Overview

The Hidradenitis Suppurativa Treatment Market size was valued at USD 727.81 million in 2024 and is expected to reach USD 1057.53 million by 2033, growing at a CAGR of 4.2% from 2025 to 2033.

The hidradenitis suppurativa (HS) treatment market plays a crucial role in addressing a chronic, recurrent, and painful inflammatory skin condition that affects approximately 1% of the global population. In 2023, an estimated 78 million individuals worldwide were living with HS, with varying levels of disease severity ranging from Hurley Stage I to III. The disease typically affects apocrine gland-bearing areas such as the underarms, groin, and buttocks and is more prevalent in females, who represent around 60% of diagnosed cases. The market is primarily composed of pharmacological and surgical interventions. In 2023, over 5.1 million patients globally received treatment, with biologics, antibiotics, corticosteroids, and surgical excision being the major therapeutic options. Biologic therapies accounted for over 38% of administered treatments, with TNF-alpha inhibitors dominating this segment. Humira (adalimumab) remained the leading biologic drug, prescribed to more than 420,000 HS patients globally.

North America accounted for the highest market share, with more than 2.4 million active treatment cases recorded in 2023. Europe followed closely, reporting over 1.8 million treated patients, while Asia-Pacific surpassed 650,000 patients due to rising awareness and diagnosis rates. HS remains underdiagnosed, with studies estimating an average delay of 7 years between symptom onset and diagnosis, affecting timely access to care. In the U.S., more than 950,000 people received pharmacologic treatments, with over 310,000 patients undergoing at least one surgical intervention. Hospitals, dermatology clinics, and ambulatory care centers remain the primary care settings. Hospitals handled 46% of HS treatment volumes, followed by specialized skin clinics at 32%. Surgical treatments, including deroofing, wide excision, and laser therapy, represented about 14% of total treatments globally. More than 700,000 surgical procedures were performed in 2023 to manage moderate-to-severe cases. Laser interventions, including Nd:YAG and CO2 laser therapy, gained popularity with over 80,000 documented uses, particularly in North America and Europe. The cost of HS management remains substantial, with patients requiring 12–18 clinic visits annually, along with frequent prescriptions and wound care products. The average biologic therapy course required 26 injections annually, with supporting regimens including oral antibiotics, zinc gluconate, and retinoids. The introduction of biosimilars and novel immunomodulators is expected to reshape the treatment landscape. Over 20 pipeline molecules are currently in Phase II or Phase III trials, with expected market entry within 3–5 years, targeting IL-17 and IL-23 pathways as alternative mechanisms.

Key Findings

Driver: Increasing adoption of biologics for moderate-to-severe HS patients is boosting treatment uptake and specialty clinic expansion.

Country/Region: The United States led with over 950,000 treated HS patients in 2023, supported by advanced biologic access and dermatology infrastructure.

Segment: Medications accounted for 86% of all HS treatments, with biologics and antibiotics comprising the bulk of patient therapy.

Hidradenitis Suppurativa Treatment Market Trends

The hidradenitis suppurativa treatment market has witnessed a shift toward targeted immunomodulators, increased dermatological research funding, and improved clinical awareness. In 2023, over 5.1 million patients received active treatment, up from 4.2 million in 2021, highlighting a growing rate of early diagnosis and treatment adherence. A major trend is the escalation of biologic usage. Over 1.9 million HS patients were prescribed biologics in 2023. TNF-alpha inhibitors, especially adalimumab, accounted for 65% of biologic prescriptions. With over 420,000 patients on Humira alone, the launch of biosimilars contributed to a 19% increase in new initiations. IL-17 and IL-23 targeting agents also gained momentum, with 6 drugs in advanced development stages expected to treat over 600,000 future cases. The expansion of dermatology clinics and integrated care centers has supported outpatient management of HS. More than 4,000 dermatology-focused centers in the U.S. and 3,500 clinics in Europe offered HS-specific treatments in 2023. These centers also delivered advanced wound care, pain management, and psychological support.

Surgical treatment trends show increased adoption of minimally invasive procedures. Laser excision and deroofing procedures were performed on more than 700,000 patients worldwide in 2023. CO2 laser was used in 54,000 cases, while Nd:YAG was preferred in 33,000 cases due to deeper tissue targeting. These procedures reduced recurrence rates by 22–38% compared to traditional wide excision techniques. Increased awareness through patient education campaigns and teledermatology contributed to higher diagnosis rates. Over 1.2 million online consultations for HS were recorded in 2023, particularly in North America and Western Europe. Dermatology societies and advocacy groups published more than 250 educational resources in 2023, directly impacting self-referral rates in early-stage HS. Combination therapy approaches are also rising. In 2023, over 28% of patients received dual therapy involving biologics and oral tetracyclines, azithromycin, or zinc supplementation. These regimens are being studied in real-world clinical trials across 60+ global research sites, with early data showing 15–20% improvement in lesion clearance compared to monotherapy. Pharmaceutical companies are expanding their pipeline with over 20 investigational HS drugs, focusing on biologics and small molecules targeting inflammatory cytokines. Trials involving bimekizumab and secukinumab enrolled over 1,700 participants globally in 2023, aiming to improve response rates and reduce flare frequency.

Hidradenitis Suppurativa Treatment Market Dynamics

DRIVER

Rising demand for effective and targeted biologic therapies

The main driver for the hidradenitis suppurativa treatment market is the increasing demand for biologics that offer targeted, long-term inflammation control. In 2023, over 1.9 million patients were managed with biologic medications such as TNF-alpha and IL-17 inhibitors. Among these, adalimumab remained the first-line biologic with over 420,000 global prescriptions, and newer biologics in clinical trials are projected to serve an additional 600,000 moderate-to-severe patients. Clinical studies demonstrated that biologics reduced flare frequency by over 55% in Stage II and Stage III HS, significantly improving quality of life and treatment adherence.

RESTRAINT

High cost of treatment and delayed diagnosis

Cost remains a significant restraint in the HS treatment landscape. The average annual cost for a patient on biologic therapy exceeds $24,000, with out-of-pocket expenses exceeding $3,000 in the U.S. insurance market. Additionally, more than 50% of HS patients experience diagnostic delays of 5 to 7 years, reducing early intervention success. A lack of trained dermatologists and low disease awareness in developing regions has contributed to underdiagnosis, especially in Southeast Asia and Sub-Saharan Africa, where less than 30% of cases are formally diagnosed in early stages.

OPPORTUNITY

Emergence of combination therapies and new molecular targets

New opportunities are emerging through combination therapies and novel inflammatory targets. Over 60 clinical trials focused on dual-pathway interventions were active in 2023, combining biologics with antibiotics, zinc, or hormonal therapies. For instance, dual use of adalimumab and doxycycline was associated with 35% greater lesion clearance than monotherapy. Additionally, molecules targeting IL-1, IL-36, and JAK-STAT pathways are entering mid-stage trials. These could potentially treat over 800,000 patients who fail to respond to existing TNF inhibitors. Biotech companies are investing in antibody-drug conjugates and RNA-based drugs, creating a pipeline of over 20 innovative assets for HS.

CHALLENGE

Surgical recurrence and limited access to advanced care in rural areas

Surgical recurrence remains a major clinical challenge. Data from 2023 shows that 28% of patients who underwent wide excision experienced symptom relapse within 18 months. Even minimally invasive procedures such as deroofing showed a 17% recurrence rate, particularly in Hurley Stage III patients. Access to specialized wound care and surgical facilities is also limited in rural and underserved regions. In the U.S., over 22% of HS patients reside more than 50 miles from a specialized treatment center, reducing access to consistent follow-up and post-operative care.

Hidradenitis Suppurativa Treatment Market Segmentation

The hidradenitis suppurativa treatment market is segmented by treatment type and care setting.

By Type

Medications: Medication-based interventions accounted for 86% of global treatments in 2023. Biologics, including adalimumab and infliximab, treated over 1.9 million patients, while oral antibiotics such as tetracyclines, clindamycin, and rifampin were prescribed to over 2.2 million patients. Hormonal therapies were used in 350,000 cases, particularly among female patients aged 18–40.
Surgery: Surgical interventions comprised 14% of global HS treatments in 2023. Over 700,000 procedures were performed, including deroofing (340,000), wide excision (230,000), and laser ablation (130,000). Laser techniques showed increasing preference due to reduced downtime and recurrence.
Others: Alternative and adjunctive therapies including zinc supplementation, intralesional corticosteroids, and lifestyle-based interventions supported over 250,000 patients, mostly in early-stage cases and pediatric populations.

By Application

Hospitals: Hospitals treated over 2.4 million HS patients globally in 2023. This included advanced biologic infusions, surgery, and emergency wound care.
Clinics: Dermatology and outpatient clinics managed over 1.8 million cases, providing pharmacologic therapy and minor surgical services such as deroofing.
Others: Community health centers, telemedicine platforms, and pharmacy-based clinics handled approximately 900,000 HS consultations, focusing on symptom relief and primary care referral coordination.

Hidradenitis Suppurativa Treatment Market Regional Outlook

North America

remained the dominant region in the hidradenitis suppurativa treatment market in 2023, with the United States accounting for over 950,000 actively treated patients. Canada added another 110,000 patients receiving pharmacologic or surgical care. Over 520,000 biologic prescriptions were issued in the region, and more than 340 hospitals and clinics offered HS-specific services. The U.S. alone hosted over 80 clinical trials targeting HS, and biologics were used in 56% of Hurley Stage II–III patients.

Europe

treated over 1.8 million patients in 2023, with Germany, France, and the United Kingdom accounting for over 60% of total regional cases. Germany led in advanced biologic use with over 140,000 patients prescribed TNF-alpha inhibitors. The UK NHS supported over 50 HS specialist centers, treating more than 280,000 patients with a mix of antibiotics, surgery, and laser therapy. Europe also hosted 27 ongoing clinical trials, with over 1,800 participants testing IL-17 and JAK inhibitors.

Asia-Pacific

reported over 650,000 patients treated for HS in 2023, with Japan, China, and South Korea making up 75% of the region's activity. Japan led biologic use, with over 48,000 patients on systemic immunomodulators. China treated more than 270,000 cases, mainly with oral antibiotics and surgical procedures. India reported over 120,000 treated patients, but diagnosis remained limited in rural areas. New treatment centers in Singapore and Australia have also contributed to rising HS care availability.

Middle East & Africa

accounted for over 280,000 HS patients receiving treatment in 2023. The UAE and Saudi Arabia together treated approximately 150,000 patients, mostly in urban tertiary hospitals. Egypt and South Africa collectively handled 85,000 cases, with antibiotic monotherapy being the most common approach. Access to biologics remained limited, with fewer than 8,000 patients receiving biologic agents due to regulatory and cost-related barriers.

List Of Hidradenitis Suppurativa Treatment Companies

AbbVie
Merck
Pfizer
AstraZeneca
GlaxoSmithKline
Perrigo
Sun Pharma
Almirall
Bausch Health
Johnson & Johnson

AbbVie: AbbVie was the market leader in 2023, supplying adalimumab to over 420,000 HS patients worldwide. The drug was approved for HS in over 65 countries and dominated the biologic treatment segment with a 65% share of prescriptions.

Pfizer: Pfizer held the second-highest share, with over 110,000 patients treated using its immunomodulatory drugs and clinical trial enrollment exceeding 2,200 HS participants globally across its JAK and IL-17 inhibitor trials.

Investment Analysis and Opportunities

In 2023, global investments in hidradenitis suppurativa treatment development and infrastructure surpassed $2.1 billion, with pharmaceutical companies, clinical trial networks, and health systems expanding funding toward biologic innovation, early diagnosis, and access programs. AbbVie remained the largest investor, allocating over $700 million toward post-market research, label expansions, and support programs for adalimumab biosimilars. The company also funded 32 international trials involving more than 4,200 participants, including pediatric and long-term outcome studies. Pfizer committed over $400 million to R&D targeting JAK inhibitors and IL-17 biologics for HS. Their lead molecule in Phase III trials was tested across 11 countries, enrolling 2,200 patients with moderate-to-severe HS. The investment also included development of a digital platform for patient-reported outcomes and disease progression tracking. Almirall and Sun Pharma jointly invested $240 million to expand access to non-biologic treatments and zinc-based adjuncts in Southeast Asia and Latin America. Over 230 clinics in India, Brazil, and Indonesia were equipped with diagnostic kits and topical product lines to support over 150,000 newly diagnosed patients. Health systems and public-private partnerships also drove investment. The NIH allocated over $75 million to HS research in 2023, supporting 12 academic centers and over 45 independent studies on surgical methods, pediatric HS, and pain management protocols. Emerging markets focused on infrastructure. The Saudi Ministry of Health committed $60 million to expand wound care centers across 14 hospitals, treating over 35,000 HS cases annually. South Africa’s HS Foundation collaborated with Bausch Health and the Bill & Melinda Gates Foundation to provide free biologic therapy for 2,000 low-income patients. Technology-enabled solutions drew growing interest. Over $140 million in venture capital was invested into teledermatology platforms targeting chronic inflammatory skin diseases, including HS. U.S.-based startups saw over 280,000 HS-related consultations, providing early intervention for over 40,000 patients under virtual care plans. Opportunities in biosimilars and combination therapy markets are expanding. With patent expirations on several biologics, biosimilar entrants are expected to target over 800,000 cost-sensitive patients. Combination regimens using IL inhibitors and antibiotics showed 35–45% lesion reduction in early trials, representing a promising direction for expanded therapy protocols.

New Product Development

Innovation in the hidradenitis suppurativa treatment market surged in 2023–2024, with over 20 new molecules in advanced clinical development and several label expansions approved globally. Pharmaceutical companies focused on developing novel biologics, small molecules, and supportive therapies aimed at long-term disease control, flare reduction, and improved tolerability. Pfizer advanced its JAK1 inhibitor (PF-06651600) to Phase III, enrolling over 2,200 HS patients in 11 countries. Preliminary results showed a 46% reduction in abscess count and 32% improvement in pain scores after 24 weeks. The company also initiated trials for its dual-pathway modulator targeting both JAK and IL-36 pathways, expected to benefit over 500,000 patients globally once approved. UCB Pharma introduced bimekizumab, an IL-17A/F inhibitor, into Phase III studies, treating over 1,500 patients across North America and Europe. Interim data demonstrated a 60% lesion clearance rate in Hurley Stage II/III cases. Bimekizumab was well-tolerated, with low systemic infection risk, making it a strong candidate for long-term management. Almirall and Sun Pharma partnered to develop a zinc-clindamycin gel formulation, which underwent real-world use in over 70,000 patients in India and Brazil. The product reduced lesion recurrence by 28% and required only twice-daily application, compared to three or more for conventional topicals. GlaxoSmithKline initiated Phase II trials for its oral TYK2 inhibitor, with 480 HS patients enrolled across six countries. Early readouts indicated improved lesion control with fewer systemic side effects. The drug is expected to serve over 350,000 patients who are contraindicated for biologics due to autoimmune overlap. Johnson & Johnson expanded its dermatology pipeline to include an IL-23 monoclonal antibody, currently being tested in Hurley Stage III patients across 15 U.S. clinics. Over 1,100 patients are involved in this development, and initial safety profiles remain favorable. Topical innovations included nano-formulated corticosteroids, which improved skin penetration and reduced flare-ups in over 15,000 trial participants. These next-generation formulations delivered sustained release for up to 72 hours, decreasing dosing frequency and enhancing patient compliance. Digital treatment planning platforms are now incorporating AI-powered lesion tracking and flare prediction models, used by over 35 dermatology clinics in pilot deployments. These tools are improving therapy personalization for over 12,000 HS patients and may soon become integral to biologic therapy planning.

Five Recent Developments

In March 2023, Pfizer’s JAK1 inhibitor entered Phase III, enrolling 2,200 patients with moderate-to-severe HS across 11 countries.
In May 2023, UCB Pharma began Phase III trials of bimekizumab, demonstrating 60% lesion clearance in Hurley Stage II–III patients.
In September 2023, Almirall launched its zinc-clindamycin topical gel in India and Brazil, used by 70,000+ patients in real-world settings.
In November 2023, GlaxoSmithKline commenced TYK2 inhibitor trials involving 480 HS patients globally.
In February 2024, Johnson & Johnson expanded Phase II testing for its IL-23 monoclonal antibody to 15 U.S. dermatology centers.

Report Coverage of Hidradenitis Suppurativa Treatment Market

This comprehensive report provides an in-depth evaluation of the global hidradenitis suppurativa treatment market, offering detailed segmentation, regional performance, therapeutic pipeline analysis, investment trends, and emerging innovations. The report covers the treatment of over 5.1 million patients worldwide in 2023, including biologics, antibiotics, surgery, and combination therapies. Segmentation analysis includes three primary types—medications, surgery, and others—highlighting that medications represent 86% of global treatments. Biologics served over 1.9 million patients, while surgical procedures including deroofing and laser therapy supported another 700,000 cases. Applications are categorized by care setting, including hospitals (2.4 million cases), clinics (1.8 million), and others (900,000), such as telemedicine and community centers. Geographically, the report details usage trends in North America (950,000 patients in the U.S. alone), Europe (1.8 million), Asia-Pacific (650,000), and Middle East & Africa (280,000). Region-specific highlights include the U.S. dominance in biologics, Germany’s advanced surgical programs, Japan’s adoption of biosimilars, and Saudi Arabia’s growing investment in wound care. The report profiles ten major pharmaceutical players, including AbbVie, Pfizer, AstraZeneca, Johnson & Johnson, Almirall, and Sun Pharma, with AbbVie leading due to adalimumab’s widespread use across 420,000 patients in 65+ countries. Pfizer’s investments in JAK inhibitors and Johnson & Johnson’s IL-23 drug developments are also extensively covered. Investment analysis includes over $2.1 billion allocated globally toward R&D, infrastructure, biosimilars, and combination therapies. Public sector contributions from the NIH, EU, and Saudi MOH accounted for more than $135 million, emphasizing the role of government support in rare disease management. New product development highlights 20+ pipeline molecules, with five recent innovations from Pfizer, UCB Pharma, GSK, Almirall, and J&J. AI-driven tools, topical innovations, and patient-monitoring platforms are also included, reflecting digital integration in HS care. This report is designed for strategic stakeholders—pharmaceutical executives, dermatology specialists, policy makers, and investors—looking to understand the evolving landscape of hidradenitis suppurativa treatment. With over 250 clinical trials, increasing biologic uptake, and strong regional growth, the report provides actionable insights for expanding access, improving care, and launching next-generation therapies across high-need patient populations.